Elgn-2112
Malabsorption Syndrome
Elgan Pharma Ltd.UNKNOWNPhase 3Active
BB
66/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 52/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Malabsorption Syndrome cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Tannic Acid Hospital Infantil Cândido Fontoura | Phase 3 | BB |
Lidocaine Hospital Infantil Cândido Fontoura | Phase 3 | BB |
Nexvax2 ImmusanT, Inc. | Phase 2 | B |
Ntra-2112 Elgan Pharma Ltd. | Phase 3 | B |
Crofelemer Napo Therapeutics, S.p.A. | Phase 2 | CCC |
Lactose Ureide University Hospital, Bonn | Unknown | D |
Calcium Hvidovre University Hospital | N/A | D |
Vandazole HaEmek Medical Center, Israel | N/A | D |
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →